Vision Loss Clinical Trials
A listing of Vision Loss medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 69 clinical trials
Randomized, Double Blind, Placebo-Controlled Trial of the Safety and Efficacy of HORIZANT® (Gabapentin Enacarbil) Extended-Release Tablets for the Treatment of Alcohol Use Disorder
Alternating phone and in-clinic visits for medical management (MM), laboratory tests, and physical exams, to assess drug compliance, to complete additional questionnaires, and to provide counseling (via “Take Control” videos) over 29 weeks.
- 0 views
- 19 Feb, 2024
- 1 location
A multi-center double-blind placebo-controlled Phase 4 study in patients with pulmonary arterial hypertension to assess the effect of selexipag on daily life physical activity and patients self-reported symptoms and their impacts
This is a prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group, exploratory Phase 4 study. The purpose is to identify the effect of selexipag on daily life physical activity assessed by a wearable device in patients with PAH (WHO Group 1).
- 0 views
- 19 Feb, 2024
- 1 location
DEVELOPING ORAL LT3 THERAPY FOR HEART FAILURE (DOT3HF)
Parallel, Randomized, Double-Blind, Placebo-Controlled Crossover Clinical Trial The primary objective is to evaluate the safety of oral LT3 in heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) The secondary objective is to evaluate the feasibility and preliminary efficacy outcomes of oral LT3 therapy …
- 0 views
- 19 Feb, 2024
- 1 location
A Phase 2B Randomized Double-Blind Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults with Nonalcoholic Steatohepatitis (NASH) and Compensated Liver Cirrhosis
A phase 2B, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of BMS-986036 in subjects with NASH and compensated cirrhosis. The treatment period is 48 weeks, with drug administered as a once-weekly injection.
- 0 views
- 19 Feb, 2024
- 1 location
A randomized double-blind placebo-controlled parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimers Disease (AD)
The study will enroll cognitively unimpaired individuals who are between the ages of 60-75 years with at least one APOE4 allele (HMs or HTs) and, if HTs, with evidence of elevated brain amyloid. Cognitively unimpaired subjects defined as having a Mini-Mental State Examination (MMSE) total score greater than or equal …
- 0 views
- 19 Feb, 2024
- 1 location
The Randomized And Controlled Non-inferiority Trial to Evaluate Safety and Clinical Efficacy of the SurVeil Drug-Coated Balloon iN the Treatment of Subjects with Stenotic Lesions of the Femoropopliteal Artery Compared to the Medtronic IN.PACT Admiral Drug-Coated Balloon
Prospective, multi-center, single-blind, randomized, controlled, noninferiority clinical trial. The trial will randomize approximately 446 subjects (at approximately 60 sites in the US and 18 sites outside the US) with symptomatic PAD due to stenoses of the femoral and/or popliteal arteries.
- 0 views
- 19 Feb, 2024
- 1 location
A Phase 3 Multicenter Randomized Double-blind Placebo-controlled Trial to Evaluate the Efficacy Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder
This trial is a phase 3, double-blind, placebo-controlled, randomized withdrawal maintenance trial of brexpiprazole in subjects who require adjunctive treatment of MDD designed to fulfill a post-marketing commitment to the US Food and Drug Administration (FDA).
- 0 views
- 19 Feb, 2024
- 1 location